Jette Tjornelund
Overview
Explore the profile of Jette Tjornelund including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
324
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Calvo E, Reddy G, Boni V, Garcia-Canamaque L, Song T, Tjornelund J, et al.
Invest New Drugs
. 2016 Jan;
34(2):193-201.
PMID: 26769244
Background: Belinostat, a potent pan-inhibitor of histone deacetylase (HDAC) enzymes, is approved in the United States (US) for relapsed/refractory peripheral T-cell lymphoma. In nonclinical studies, bile and feces were identified...
2.
Christensen M, Erichsen K, Olesen U, Tjornelund J, Fristrup P, Thougaard A, et al.
J Med Chem
. 2013 Oct;
56(22):9071-88.
PMID: 24164086
Existing pharmacological inhibitors for nicotinamide phosphoribosyltransferase (NAMPT) are promising therapeutics for treating cancer. By using medicinal and computational chemistry methods, the structure-activity relationship for novel classes of NAMPT inhibitors is...
3.
Kiesel B, Parise R, Tjornelund J, Christensen M, Loza E, Tawbi H, et al.
J Pharm Biomed Anal
. 2013 May;
81-82:89-98.
PMID: 23644904
The histone deacetylase inhibitor belinostat is being evaluated clinically as a single agent in the treatment of peripheral T-cell lymphomas and in combination with other anticancer agents to treat a...
4.
Christensen M, Erichsen K, Trojel-Hansen C, Tjornelund J, Nielsen S, Frydenvang K, et al.
J Med Chem
. 2010 Sep;
53(19):7140-5.
PMID: 20845961
Optimization of the anticancer activity for a class of compounds built on a 1,3-dihydroindole-2-one scaffold was performed. In comparison with recently published derivatives of oxyphenisatin the new analogues exhibited an...
5.
The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies
Nahimana A, Attinger A, Aubry D, Greaney P, Ireson C, Thougaard A, et al.
Blood
. 2009 Feb;
113(14):3276-86.
PMID: 19196867
APO866 inhibits nicotinamide phosphoribosyltransferase (NMPRTase), a key enzyme involved in nicotinamide adenine dinucleotide (NAD) biosynthesis from the natural precursor nicotinamide. Intracellular NAD is essential for cell survival, and NAD depletion...
6.
Martin E, Thougaard A, Grauslund M, Jensen P, Bjorkling F, Hasinoff B, et al.
Toxicology
. 2008 Nov;
255(1-2):72-9.
PMID: 19010377
Anthracycline-induced cardiomyopathy is a major problem in anti-cancer therapy. The only approved agent for alleviating this serious dose limiting side effect is ICRF-187 (dexrazoxane). The current thinking is that the...
7.
Dejligbjerg M, Grauslund M, Christensen I, Tjornelund J, Jensen P, Sehested M
Cancer Biomark
. 2008 May;
4(2):101-9.
PMID: 18503161
Histone deacetylase inhibitors (HDACi) are promising epigenetic cancer chemotherapeutics rapidly approaching clinical use. HDACi increases acetylation levels of histone and non-histone proteins and causes an alteration in gene-expression levels, ultimately...
8.
Steele N, Plumb J, Vidal L, Tjornelund J, Knoblauch P, Rasmussen A, et al.
Clin Cancer Res
. 2008 Feb;
14(3):804-10.
PMID: 18245542
Purpose: To determine the safety, dose-limiting toxicity, maximum tolerated dose, and pharmacokinetic and pharmacodynamic profiles of the novel hydroxamate histone deacetylase inhibitor belinostat (previously named PXD101) in patients with advanced...
9.
Warren K, McCully C, Dvinge H, Tjornelund J, Sehested M, Lichenstein H, et al.
Cancer Chemother Pharmacol
. 2007 Oct;
62(3):433-7.
PMID: 17960383
Purpose: Histone deacetylases (HDAC) are involved in the regulation of gene transcription. Aberrant HDAC activity has been associated with tumorigenesis, and, therefore, HDACs are potential targets for the treatment of...
10.
Lykkeberg A, Sengelov G, Cornett C, Tjornelund J, Hansen S, Halling-Sorensen B
J Pharm Biomed Anal
. 2004 May;
34(3):559-67.
PMID: 15127812
2-Acetyl-2-decarboxamido-oxytetracycline (ADOTC) is a major impurity of oxytetracycline (OTC) produced as a side product during fermentation. ADOTC was isolated from OTC and other impurities using preparative HPLC. The preparative column...